News
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for ...
The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback